TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7890055
Drug: Chronic low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chronic low-dose regimen of urinary human FSH or recombinant human FSH
Study: 37853
Drug: Mefenorex (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefenorex (40 mg)
Study: 37853
Drug: Fenetylline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenetylline (50 mg)
Study: 7082858
Drug: Corynebacterium parvum
Normalized name: Corynebacterium parvum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corynebacterium parvum administered intravenously on day 15 of the cytostatic cycle (group I)
Study: 7082858
Drug: Corynebacterium parvum
Normalized name: Corynebacterium parvum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corynebacterium parvum administered intravenously on day 1 of the cytostatic cycle (group II)
Study: 7082858
Drug: No administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: No administration of Corynebacterium parvum (group III)
Study: 22713999
Drug: Acetaminophen plus
Normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen plus codeine plus caffeine (T3)
Study: 20555373
Drug: Fish-oil supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil supplement (approximately 1 g EPA and DHA)
Study: 17907479
Drug: Ozone treatment
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone treatment and a root sealant applied to root caries lesions
Study: 11513907
Drug: WHO short-course
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO short-course chemotherapy
Study: 11513907
Drug: Russian tuberculosis
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Russian tuberculosis treatment
Study: 9051390
Drug: rhIGF‐I (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I (80 mcg/kg s.c.)
Study: 29121961
Drug: Pain education
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain education program (treatment as usual)
Study: 18979504
Drug: Beta-glucan muesli
Normalized name: Beta glucan
DrugBank: Yeast beta-D-glucan (DB19271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-glucan muesli (4.8 g oat beta-glucan)
Study: 18979504
Drug: Combination muesli
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination muesli (4.8 g oat beta-glucan plus 1.4 g stanol as PSE)
Study: 18979504
Drug: Control muesli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control muesli (4.8 g control fiber)
Study: 18979504
Drug: Beta-glucan muesli
Normalized name: Beta glucan
DrugBank: Yeast beta-D-glucan (DB19271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-glucan muesli and Combination muesli
Study: 14738235
Drug: DNK333 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNK333 (100 mg)
Study: 9661678
Drug: Corticotropin-releasing hormone
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin-releasing hormone (CRH) at 2.5 micrograms/kg/hr
Study: 9661678
Drug: Corticotropin-releasing hormone
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin-releasing hormone (CRH) at 4.0 micrograms/kg/hr
Study: 7923825
Drug: 5% saline
Normalized name: Breathe Free 0.65% Saline Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% saline infusion (0.06 ml/kg/h)
Study: 7923825
Drug: 20% mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% mannitol infusion (0.07 ml/kg/h)
Study: 2894902
Drug: Atracurium (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.4 mg.kg‐1)
Study: 2894902
Drug: d-tubocurarine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-tubocurarine (0.8 mg.kg‐1)
Study: 2894902
Drug: Pancuronium (0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (0.12 mg.kg‐1)
Study: 2894902
Drug: Vecuronium (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.07 mg.kg‐1)
Study: 25675317
Drug: Aftercare treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aftercare treatment (2-4 interview contacts via telephone or face-to-face within the first 3 months after discharge)
Study: 21478141
Drug: High-voltage stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-voltage stimulation (HVS) with drug therapy
Study: 21478141
Drug: Ultrasound with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound with drug therapy
Study: 21478141
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with drug therapy
Study: 21478141
Drug: Compression stockings
Normalized name: Truform Medical Compression Stockings
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression stockings with drug therapy
Study: 21478141
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy only
Study: 21478141
Drug: Conservative HVS
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conservative HVS with drug therapy
Study: 21478141
Drug: Conservative ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative ultrasound with drug therapy
Study: 21478141
Drug: Conservative LLLT
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative LLLT with drug therapy
Study: 21478141
Drug: Conservative compression
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conservative compression with drug therapy
Study: 19515730
Drug: HD-FPV/RTV (1400
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD-FPV/RTV (1400 mg/100 mg twice daily)
Study: 19515730
Drug: FPV/LPV/RTV (1400
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPV/LPV/RTV (1400 mg/533 mg/133 mg twice daily)
Study: 19515730
Drug: STD-FPV/RTV (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: STD-FPV/RTV (700 mg/100 mg twice daily)
Study: 17368232
Drug: Sham feedback
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham feedback therapy
Study: 7979842
Drug: Traditional internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional internal medicine clerkship (n=69)
Study: 7979842
Drug: Ambulatory medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory medicine and ward medicine (n=38)
Study: 7979842
Drug: Overall attitudes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall attitudes towards internal medicine training
Study: 30606271
Drug: Lurasidone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (20 mg)
Study: 23837278
Drug: Tramadol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (50 mg in 10 mL normal saline)
Study: 15830221
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg alprazolam
Study: 15830221
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg alprazolam
Study: 15605689
Drug: Doxycin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycin (100 mg)
Study: 11705752
Drug: Clonidine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (up to 0.3 mg po)
Study: 11705752
Drug: Clonidine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.3 mg po)
Study: 11705752
Drug: Clonidine (as
Normalized name: clonidine (as clonidine hydrochloride)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (as low as 0.05 mg)
Study: 9717652
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of timolol 0.5% and latanoprost 0.001% (comb. 10)
Study: 9717652
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of timolol 0.5% and latanoprost 0.005% (comb. 50)
Study: 6843197
Drug: Technicians dispensing
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Technicians dispensing prescriptions
Study: 6843197
Drug: Pharmacists dispensing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacists dispensing prescriptions
Study: 6843197
Drug: Pharmacists counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacists counseling patients after technicians began dispensing prescriptions
Study: 28375792
Drug: Idracemi, 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idracemi, 0.3% cortisol phosphate eye drops twice a day
Study: 28375792
Drug: Cortivis, 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortivis, 0.3% cortisol phosphate in hyaluronic acid vehicle, twice a day
Study: 21841500
Drug: Valsartan 640
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan 640 mg/day
Study: 11465651
Drug: Valsartan 320
Normalized name: valsartan 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 320 mg/day
Study: 21841500
Drug: Valsartan (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (all doses)
Study: 21653528
Drug: Combination antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antiretroviral therapy (ART)
Study: 17161118
Drug: NETA/EE-24 (24-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: NETA/EE-24 (24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g)
Study: 17161118
Drug: NETA/EE-21 (21-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: NETA/EE-21 (21-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g)
Study: 7972620
Drug: Beta-blocking drug
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocking drug (Bisoprolol)
Study: 168645
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine oestrogen (Premarin) 1.25 mg
Study: 168645
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine oestrogen (Premarin) 2.5 mg
Study: 21681533
Drug: Dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 4 mg (Group L)
Study: 21681533
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg (Group H)
Study: 16549931
Drug: IL-6 infusion
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 infusion (n = 6)
Study: 16549931
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (n = 6)
Study: 12759270
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (100 micro g in each nostril)
Study: 12759270
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of loratadine (10 mg) and montelukast sodium (10 mg) by mouth once daily
Study: 9109607
Drug: Oral iodized
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iodized oil (100 mg)
Study: 3301517
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (both doses)
Study: 15206484
Drug: Inositol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inositol (100 mg, twice a day)
Study: 3912112
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of cyclothiazide daily
Study: 3912112
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of hydrochlorthiazide daily
Study: 3912112
Drug: Increasing doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing doses of cyclothiazide or hydrochlorthiazide
Study: 30970404
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with standardized dust mite vaccine and conventional drugs
Study: 30970404
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and conventional drugs (Control)
Study: 30239842
Drug: Intravaginal testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal testosterone (IVT) cream (300 μg per dose), self-administered daily for 2 weeks and then thrice weekly for 24 weeks
Study: 30239842
Drug: Intravaginal testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal testosterone (IVT) cream
Study: 27696203
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (ATRA) 45 mg/m2 (days 6-8); 15 mg/m2 (days 9-21)
Study: 25102884
Drug: Compound Borax
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Borax Solution
Study: 19155235
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous cyclophosphamide (LD IVCY) followed by azathioprine (AZA)
Study: 19155235
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous cyclophosphamide (HD IVCY) followed by azathioprine (AZA)
Study: 15699223
Drug: High-calorie complex
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calorie complex carbohydrate (HC-CC) meal
Study: 15699223
Drug: All meals
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: All meals (HC-SC, HC-CC, LC)
Study: 15699223
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and Leptin
Study: 12854476
Drug: PGE1 infusion
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE1 infusion at a rate of 0.01 microgram.kg‐1.min‐1 during and after the operation (60‐80 hrs)
Study: 8605674
Drug: Cancer antigen
Normalized name: Cancer antigen 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen assessment during therapy
Study: 31111049
Drug: HPVADL18® (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPVADL18® (200 mg Echinacea Purpurea and Echinacea Angustifolia) for 4 months after laser therapy
Study: 31111049
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional therapy (Control Group B)
Study: 26120407
Drug: Oxytocin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (50 units in 500 cc normal saline, increased to maximum 300 units) with laminaria (6 hours)
Study: 21205237
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue plasminogen activator (3-6 h after symptom onset)
Study: 21205237
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue plasminogen activator (3-4.5 h after symptom onset)
Study: 21205237
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue plasminogen activator (4.5-6 h after symptom onset)
Study: 21205237
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue plasminogen activator
Study: 16426264
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg subcutaneous sumatriptan (early administration)
Study: 16426264
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg subcutaneous sumatriptan (late administration)
Study: 11296099
Drug: Continuation-phase cognitive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation-phase cognitive therapy (C‐CT) for 8 months (10 sessions)
Study: 8500499
Drug: Oxyprogesterone caproate
Normalized name: Hydroxyprogesterone Caproate
DrugBank: Hydroxyprogesterone caproate (DB06789)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxyprogesterone caproate (OPC) administered preoperatively and after surgical and combined therapy for 6 to 36 months
Study: 8500499
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Oxyprogesterone caproate (OPC) and Tamoxifen administered additionally to surgical and combined therapy
Study: 8500499
Drug: Adjuvant hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant hormone therapy in endometrial carcinoma patients
Study: 3566252
Drug: Cefoperazone and
Normalized name: Cefoperazone and sulbactam only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone and tobramycin in combination
Study: 18253066
Drug: A. vera
Approvals — FDA: no, EMA: no, PMDA: no
Description: A. vera gel (97.5%)
Study: 18253066
Drug: 1% hydrocortisone
Normalized name: HYDROCORTISONE 0.01 g in 1 g TOPICAL OINTMENT [AFASSCO 1% Hydrocortisone]
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1% hydrocortisone in placebo gel
Study: 15986873
Drug: pegIFNalpha‐2a (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegIFNalpha‐2a (180 microg/week) plus ribavirin (800 mg/day)
Study: 8696717
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m2, escalated by 250 mg/m2/week to 1750 mg/m2) and Cisplatin (25 mg/m2 escalated to 30 mg/m2) administered as 30 min infusions weekly x 3 with a week of rest.
Study: 6133802
Drug: Azatadine maleate/pseudoephedrine
Normalized name: Azatadine Maleate/Pseudoephedrine Sulfate 1 MG-120 MG Oral Tablet, Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azatadine maleate/pseudoephedrine sulfate syrup
Study: 25498742
Drug: Abdominal massage
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal massage administered twice daily for 15 minutes
Study: 23323626
Drug: Local anaesthetic
Normalized name: Local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthetic injection (bupivacaine) during banding
Study: 23323626
Drug: No local
Approvals — FDA: no, EMA: no, PMDA: no
Description: No local anaesthetic injection (control)
Study: 20821330
Drug: 5-FU (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU (400 mg/m2 bolus, 600 mg/m2 22 h continuous infusion day 1 and 2) + cisplatin (50 mg/m2 day 1) + pegylated liposomal doxorubicin (20 mg/m2 day 1 every two weeks)
Study: 20821330
Drug: 5-FU (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU (400 mg/m2 bolus, 600 mg/m2 22 h continuous infusion day 1 and 2) + cisplatin (50 mg/m2 day 1) + mitomycin-C (7 mg/m2 every 6 weeks)
Study: 20006142
Drug: A/Vietnam/1194/2004 A/H5N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/Vietnam/1194/2004 A/H5N1 vaccine (5microg, 15microg or 45microg) with a 50microg LT adjuvant patch applied over the injection site
Study: 20006142
Drug: Two-injection/two-patch 45microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-injection/two-patch 45microg HA regimen
Study: 20006142
Drug: A/Vietnam/1194/2004 A/H5N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/Vietnam/1194/2004 A/H5N1 vaccine (45microg) with LT patch on second immunization
Study: 20006142
Drug: A/Vietnam/1194/2004 A/H5N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/Vietnam/1194/2004 A/H5N1 vaccine (45microg) without LT patch
Study: 10547405
Drug: Osteopathic manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manual therapy
Study: 8690821
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of torsemide (75 mg over 24 hours with a 25 mg loading bolus)
Study: 8690821
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of torsemide (100 mg)
Study: 2062989
Drug: Midazolam (6.13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (6.13 mg)
Study: 2062989
Drug: Diazepam (6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (6.4 mg)
Study: 31996543
Drug: Norepinephrine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine (8 μg bolus)
Study: 31996543
Drug: Phenylephrine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (100 μg bolus)
Study: 16388091
Drug: Troglitazone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (600 mg/d)
Study: 12161056
Drug: Repaglinide (n=116,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (n=116, preprandially three-times daily)
Study: 12161056
Drug: Glibenclamide (n=119,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (n=119, preprandially once- or twice-daily)
Study: 2194053
Drug: 7.5mg of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5mg of dibucaine with 0.05mg of buprenorphine (G-II)
Study: 2194053
Drug: 7.5mg of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5mg of dibucaine with 0.25mg of morphine (G-III)
Study: 2194053
Drug: 7.5mg of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5mg of dibucaine with 0.25mg of morphine and 0.2mg of naloxone (G-IV)
Study: 2194053
Drug: 7.5mg of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5mg of dibucaine only (G-I)
Study: 348378
Drug: Para-aminosalicylic acid
Normalized name: Para-aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Para-aminosalicylic acid (PAS) 6 gm daily for 4 weeks
Study: 348378
Drug: Para-aminosalicylic acid
Normalized name: Para-aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Para-aminosalicylic acid (PAS) 6 gm daily for 4 weeks in hypercholesterolemic patients
Study: 348378
Drug: Para-aminosalicylic acid
Normalized name: Para-aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Para-aminosalicylic acid (PAS) 6 gm daily for 4 weeks in hypertriglyceridemia type IV patients
Study: 31927569
Drug: Cognitive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive and behavioral therapy for insomnia (CBTi) over 4 weeks (n=72)
Study: 31927569
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control (n=73)